Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer
- 1Duke Cancer Institute Center for Prostate and Urologic Cancers, Department of Medicine, Division of Medical Oncology, Duke University, Durham, NC 27710 USA
- 2Department of Biostatistics, Duke University, Durham, NC USA
Abstract
Background: Identifying clinical and genomic predictors of response to androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) for metastatic androgen pathway modulator sensitive (APMS) prostate cancer is essential for improving therapeutic decision-making. Divergent outcomes are observed in practice, with some achieving exceptional responses (ER) while others experience early resistance or non-response (NR), the biologic basis of which remains unclear.
Methods: A retrospective review was conducted of patients with APMS prescribed ADT/ARPI from 2015–2024. ER and NR were defined by upper ( > 53.36 months) and lower ( < 10.41 months) quartiles of progression-free survival (PFS). Objectives were to associate baseline genomic and clinical factors with ER/NR status, PFS, overall survival (OS) and PSA kinetics..
Results: Among 3363 prescribed ADT/ARPI, 224 were treated for APMS, with 154 (69%) undergoing temporal molecular testing. Alteration of ≥1 tumor suppressor gene with or without proliferative gene co-alteration was associated with NR while no single alteration predicted achieving ER. ECOG < 1, lack of pain, low-volume disease, higher hemoglobin and albumin, and normal alkaline phosphatase were associated with improved PFS, OS, and PSA nadir <0.2 ng/mL at 12 months. Alterations in TP53 (HR 1.60 [95%CI 1.02–2.50], p = 0.039; HR 1.91 [95%CI 1.05-3.49], p = 0.035) and MYC (HR 2.01 [95%CI 1.03-3.91], p = 0.040; HR 3.81 [95%CI 1.81-7.99], p < 0.001) were associated with inferior PFS and OS, while BRCA2 (HR 2.12 [95%CI 1.02–4.42], p = 0.045) additionally associated with PFS, and RAD21 (HR 2.55 [95%CI 1.13–5.77], p = 0.024) with OS. On multivariable analysis, MYC gain associated with OS (HR 4.41 [95%CI 1.24-15.7], p = 0.022). Pathway-level analysis showed proliferative gene alterations were associated with failure to achieve PSA nadir <0.2 ng/mL at 12 months (HR 0.49 [95%CI 0.24, 0.98], p = 0.047).
Conclusions: In this real-world APMS cohort, we identified pre-treatment clinical and genomic predictors of patient benefits and long-term survival with ADT/ARPI therapy.
Related
- Multi-Cycle Dosimetry of the Albumin-Binding Prostate-Specific Membrane Antigen Ligand [¹⁷⁷Lu]Ludotadipep in Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer with Adjusted Red Marrow Modeling.
- Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates.
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
- Prognostic Value of Metabolic–Muscle Reserve Index in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
- Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerations
BibTeX
@article{mckenzie2026clinical,
title = {{Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer}},
author = {Jane McKenzie and Lauren Howard and Joseph J. Park and Bilal Ashraf and Tara Seibert and Kallie White and Sundhar Ramalingam and Jeffrey W. Shevach and Michael R. Harrison and Christopher Hoimes and Matthew Labriola and Jordan Infield and Dillon Cockrell and Hannah D. McManus and Daniel J. George and Andrew J. Armstrong},
journal = {Prostate Cancer and Prostatic Diseases},
year = {2026},
month = aug,
doi = {10.1038/s41391-026-01145-0},
url = {https://doi.org/10.1038/s41391-026-01145-0},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer
AU - Jane McKenzie
AU - Lauren Howard
AU - Joseph J. Park
AU - Bilal Ashraf
AU - Tara Seibert
AU - Kallie White
AU - Sundhar Ramalingam
AU - Jeffrey W. Shevach
AU - Michael R. Harrison
AU - Christopher Hoimes
AU - Matthew Labriola
AU - Jordan Infield
AU - Dillon Cockrell
AU - Hannah D. McManus
AU - Daniel J. George
AU - Andrew J. Armstrong
PY - 2026
DA - 2026/08/05
JO - Prostate Cancer and Prostatic Diseases
DO - 10.1038/s41391-026-01145-0
UR - https://doi.org/10.1038/s41391-026-01145-0
AB - Background: Identifying clinical and genomic predictors of response to androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) for metastatic androgen pathway modulator sensitive (APMS) prostate cancer is essential for improving therapeutic decision-making. Divergent outcomes are observed in practice, with some achieving exceptional responses (ER) while others experience early resistance or non-response (NR), the biologic basis of which remains unclear. Methods: A retrospective review was conducted of patients with APMS prescribed ADT/ARPI from 2015–2024. ER and NR were defined by upper ( > 53.36 months) and lower ( < 10.41 months) quartiles of progression-free survival (PFS). Objectives were to associate baseline genomic and clinical factors with ER/NR status, PFS, overall survival (OS) and PSA kinetics.. Results: Among 3363 prescribed ADT/ARPI, 224 were treated for APMS, with 154 (69%) undergoing temporal molecular testing. Alteration of ≥1 tumor suppressor gene with or without proliferative gene co-alteration was associated with NR while no single alteration predicted achieving ER. ECOG < 1, lack of pain, low-volume disease, higher hemoglobin and albumin, and normal alkaline phosphatase were associated with improved PFS, OS, and PSA nadir <0.2 ng/mL at 12 months. Alterations in TP53 (HR 1.60 [95%CI 1.02–2.50], p = 0.039; HR 1.91 [95%CI 1.05-3.49], p = 0.035) and MYC (HR 2.01 [95%CI 1.03-3.91], p = 0.040; HR 3.81 [95%CI 1.81-7.99], p < 0.001) were associated with inferior PFS and OS, while BRCA2 (HR 2.12 [95%CI 1.02–4.42], p = 0.045) additionally associated with PFS, and RAD21 (HR 2.55 [95%CI 1.13–5.77], p = 0.024) with OS. On multivariable analysis, MYC gain associated with OS (HR 4.41 [95%CI 1.24-15.7], p = 0.022). Pathway-level analysis showed proliferative gene alterations were associated with failure to achieve PSA nadir <0.2 ng/mL at 12 months (HR 0.49 [95%CI 0.24, 0.98], p = 0.047). Conclusions: In this real-world APMS cohort, we identified pre-treatment clinical and genomic predictors of patient benefits and long-term survival with ADT/ARPI therapy.
SN - 1365-7852
SN - 1476-5608
ER -